DoD FY21 Defense University Research Instrumentation Program (DURIP)

The Department of Defense (DoD announces the Fiscal Year 2021 Defense University Research Instrumentation Program (DURIP).

DURIP is designed to improve the capabilities of accredited United States (US) institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. For-profit organizations are not eligible for DURIP funding. We refer to eligible institutions of higher education as universities in the rest of this announcement.

DURIP is part of the University Research Initiative (URI).

This program will be supplemented by additional funding provided by the Defense Established Program to Stimulate Competitive Research (DEPSCoR). Additional awards may be made to principal investigators in DEPSCoR eligible states as defined in 10 U.S.C. 2358, as amended by Pub. L. 115 91, div. A, title II, sec. 219.

IMPORTANT NOTE: Applicants should be alert for any amendments that may modify the announcement. Amendments to the original funding opportunity announcement (FOA) will be posted to the Grants.gov Webpage.

The DURIP Announcement has been amended. Amendment 2 corrects section D.5.f. on page 21 to reflect that Bibliography and References Cited are included in the page count. This amendment supersedes previous versions of this FOA. Click on the box below and navigate to the “Related Documents” tab for the full program announcement.

Department of Defense Peer Reviewed Orthopaedic Research Program

The FY20 Defense Appropriations Act provides funding to the Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP) to support innovative, high-impact, clinically-relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 PRORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY20 PRORP must address one or more of the following FY20 Focus Areas:

  • Compartment Syndrome: Novel treatment strategies to improve current diagnoses for compartment syndrome. Alternatives to intracompartmental pressure measurements are encouraged.
  • Limb Stabilization and Protection: Development and/or clinical assessment of rapid limb stabilization and novel wound protectants for severely wounded limbs to enable transport at the point of need.
  • Orthotic Devices: Refinement of high-performance novel orthotic devices designed to enhance whole person performance and decrease pain in patients with limb salvage and impairment.
  • Osseointegration: Identification of best practices to address infection, rejection, and/or failure of percutaneous osseointegrated prosthetic limbs. 
  • Retention Strategies: Development, optimization, and/or validation of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty for common combat-related musculoskeletal injuries.  Biomarker studies are excluded.  The current standard of care must be noted.  The rehabilitation strategy and the standard of care must be specified, as applicable.
    • Point of Injury: Battlefield-feasible strategies that can be utilized at or near the point of injury to allow an injured Service member to remain on duty and stay on mission without the need for immediate evacuation
    • Point of Duty: Strategies that can be utilized along the continuum of care to allow an injured Service member to return to duty without separation from Service.
  • Tissue Regeneration Therapeutics: Development of advanced tissue regeneration therapeutics in nerve, muscle (to include volumetric muscle loss), and/or composite tissue for the restoration of traumatically injured extremities.  Isolated bone or cartilage tissue engineering studies are excluded.
  • Translation of Early Findings: Translation of early research findings in the orthopaedic surgical care topic areas listed below to move the research toward clinical trials and clinical practice.
    • Soft Tissue Trauma: Strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments for anterior cruciate ligament (ACL) or shoulder instability only, to optimize return to duty, work, or reintegration
    • Fracture-Related Infection: Strategies to decrease the burden of fracture-related infections (may include prevention, early detection, or improved eradication).  Alternatives to systemic and/or local antibiotic delivery are encouraged. 

https://cdmrp.army.mil/funding/prorp

Applied Research Award – Preproposal due May 27, 2020. Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports applied research applications focused on advancing optimal treatment and restoration of function for individuals with musculo-skeletal injuries sustained during combat or combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work.
  • Proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.
  • Clinical research and clinical trials are not allowed under this award mechanism.
  • Applications must address one of the following FY20 PRORP Focus Areas:
    • Limb Stabilization and Protection
    • Retention Strategies
      • Point of Injury
      • Return to Duty
  • Osseointegration

Maximum funding of $725,000 for total costs (includes direct and indirect costs). Maximum period of performance is 3 years.

Clinical Trial Award – Preproposal due May 27, 2020.Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates.
  • Funding must support a clinical trial and may not be used for preclinical research studies.
  • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
  • Applications must address one the following FY20 PRORP Focus Areas:
    • Limb Stabilization and Protection
    • Retention Strategies
      • Point of Injury
      • Return to Duty
    • Translation of Early Findings
      • Soft Tissue Trauma
      • Fracture-Related Infection

Funding Level 1:Maximum funding of $2.25M for total costs. (includes direct and indirect costs). Maximum period of performance is years.

Funding Level 2 (Translation of Early Findings – Soft Tissue Trauma Focus Area with Rehabilitation Option): Maximum funding of $2.75M for total costs (includes direct and indirect costs). Maximum period of performance is 4 years.

Clinical Translational Research Award – Preproposal is due May 27, 2020. Independent investigators at all academic levels (or equivalent):

  • Pre-application is required; full application submission is by invitation only.
  • Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale, randomized, controlled clinical trial.
  • Funding must support clinical research studies involving humans.
  • Preliminary or published data relevant to the proposed research project are required.
  • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 12 months of the award date.
  • Applications must address one of the following FY19 PRORP CTRA Focus Areas:
    • Retention Strategies
      • Point of Injury
      • Return to Duty
    • Tissue Regeneration Therapeutics
    • Compartment Syndrome
    • Osseointegration
    • Orthotic Devices

Maximum funding of $1.5M for total costs (including direct and indirect costs). Maximum period of performance is years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website.

DOE Office of Science Accommodating Interruptions due to COVID-19

MEMORANDUM FOR APPLICANTS AND AWARDEES 

SUBJECT: Accommodating Interruptions from Coronavirus Disease 2019 (COVID-19) 

As the Department of Energy and Office of Science (SC) continue to monitor and examine the ongoing developments and impacts of the COVID-19 outbreak in the U.S. and internationally, we provide this update regarding associated disruptions that may have impacts on the research community. This guidance may be updated as circumstances change.

The Office of Science is assessing its current solicitations that have due dates that occur through mid-April to make a determination on extensions to those due dates. Please check the specific Funding Opportunity Announcement (FOA) or DOE Laboratory Announcement for the most up-to-date information.

A list of all FOAs and DOE Laboratory Announcements may be found at https://science.osti.gov/grants/FOAs/Open, and https://science.osti.gov/grants/Lab-Announcements/Open, respectively.

The Office of Science extends the following flexibilities to its applicants and awardees:

Applicants preparing a pre-application, letter of intent, or application:

If the lead principal investigator (PI) or the applicant institution are subject to a quarantine or a closure, deadlines for submitting pre-applications, letters of intent, or applications may be extended by no more than fourteen (14) days from the applicable due date. Please contact the Program Manager identified in the FOA or DOE Laboratory Announcement under which the pre-application, letter of intent, or application is being submitted prior to the applicable due date.

Awardees preparing progress reports:

If the lead principal investigator (PI) or the applicant institution are subject to a quarantine or a closure, progress reports for grants, cooperative agreements, and interagency awards may be submitted through the PAMS website at https://pamspublic.science.energy.gov as soon as practicable. Note that delays in submitting progress reports may cause unavoidable delays in continuation funding.

PIs from DOE National Laboratories should contact their program manager if there will be a delay in submitting progress reports.

Applicants and awardees preparing revised budgets or public abstracts:

If the principal investigator (PI) or the applicant institution are subject to a quarantine or a closure, revised budgets and public abstracts may be submitted through the PAMS website at https://pamspublic.science.energy.gov as soon as practicable. Note that delays in submission may cause unavoidable delays in making awards.

Awardees with changed travel plans:

The Office of Science will not consider changes to planned travel caused by the cancellation of meetings, quarantines, closures, or other public health measures to be a change in the scope of an award requiring agency prior approval. Rebudgeting funds that does not create a change in scope does not require agency prior approval.

If a meeting has been cancelled, awardees must follow their institutional travel policies to determine whether costs may be charged to an award. If institutional policy permits travelers to purchase nonrefundable items (airfare, lodging, or other) and does not require travelers to reimburse the institution for change or cancellation fees, such fees may be charged to an award. If institutional policy prohibits the purchase of nonrefundable travel or travelers are required to reimburse the institution for change or cancellation fees, such fees may not be charged to an award.

Please review the attached Q&As. You are encouraged to contact the Administrative Contact for the FOA/Laboratory Announcement or your Program Manager with any concerns or questions regarding your circumstances.

Questions and Answers (Q&As):

Q: The scientific conference my lab group was scheduled to attend has been cancelled. Can our costs be reimbursed?

A: Yes, if your institutional travel policy:

  1. Permits the purchase of nonrefundable travel, and
  2. Does not require reimbursing the institution for change or cancellation fees.

Priority should be on costs incurred by students and postdocs, not by their departments.

Q: My institution told all employees to work from home. May I request an extension to a deadline?

A: Working from home—while it may introduce some complications—should not make it impossible to complete work or meet deadlines. If closure or remote access orders by your institution has occurred within a week of the deadline, please contact your Program Manager. 

Q: My Sponsored Research Office has been closed. How do I request a deadline extension?

A: Please contact your Program Manager and include a copy of the closure order or other official notification.

Q: My Vice President for Research, who customarily signs all applications, has been quarantined. What should I do?

A: Please work with your Sponsored Research Office to determine how your institution is handling the situation. If your institution has established delegations of authority or if your Vice President for Research is capable of electronic signatures, there should be no impact on your ability to submit an application. However, if submitting an application is impossible, please contact your Program Manager.

Q: Our postdoc was quarantined after visiting family overseas. Our experiment has fallen behind schedule. Will this delay impact our continuation funding?

A: Please explain the situation—without disclosing protected personally identifiable information—in your progress report. SC may need to modify an award to be a prudent steward of taxpayer funds by delaying access to continuation funds, but SC’s interest is in seeing the research results—even if it takes longer than originally expected.

Q: What information should I include in a request for a deadline extension?

A: Please include official confirmation of the closure, quarantine, or other incident that makes a timely submission impossible. An institutional declaration requiring staff telework, in and of itself, will not warrant a deadline extension. There must be further complications that make the original deadline impossible. Requests to extend a deadline must be made before the deadline. SC does not expect to support every request for an extension.

Q: May I submit a letter of intent, preproposal, proposal, or progress report before its deadline?

A: SC always encourages prompt and timely submissions. Progress reports may not be submitted more than one month before they are due.


COVID-19 Resources for Applicants of NIH Funding

A NOTE FROM NIH REGARDING COVID-19. “The NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the HHS declared public health emergency for COVID-19. This is a rapidly evolving situation, and we are aware that many institutions are taking a variety of “social distancing” measures, including switching to telework and cancelling or postponing classes and non-essential meetings.”

“Due to the potential exceptional impact of the declared public health emergency, we want to assure our recipient community that NIH will be doing our part to help you continue your research. Our website on Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients has a list of available resources.  The resources include links to NIH Guide Notices and FAQs as well as information provided by the CDC and the WHO.  Among the CDC links are advice for institutions of higher education and advice for mental health and coping.”

“Please visit our website often as we anticipate updates.”

“Most important of all please take care – we wish you, your colleagues, and your families all the best as we deal with the current challenges.”

National Science Foundation Guidance – COVID-19

NSF encourages you to take extra precautions to protect yourselves and your families against COVID-19. If you are an NSF employee looking for guidance, please visit InsideNSF. If you are a member of the public, please visit cdc.gov.

Guidance on Coronavirus (COVID-19)

NSF Community Guidance

RAPID Research on Coronavirus (COVID-19)

For more guidance click HERE

For frequently Asked Questions, click HERE